Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Myositis Associated with the Anti-COVID-19 Covishield Vaccine

Author(s): Amal Miqdadi*, Nouhad Benmansour and Mohammed Herrag

Volume 19, Issue 1, 2023

Published on: 21 October, 2022

Page: [77 - 78] Pages: 2

DOI: 10.2174/1573398X18666220823154411

Price: $65

Abstract

Introduction: The SARS-CoV-2 made the world stop its activities, and the only chance of returning to normal life is the vaccine. But like any vaccination, some complications have been reported. We report the case of a patient who presented a myositis following the administration of the Covishield* (AZD1222, ChAdOx1 nCoV-19, AstraZeneca) COVID-19 vaccine.

Case Report: 12 hours after his first dose, an 84-year-old patient presented to us reporting a decreased muscle strength: the patient can move against gravity but not against resistance. The biological assessment showed that CK was at 4,250 IU/L, myoglobin was at 144 microgram/L and aldolases at 16.9 U/L. The patient received high doses of corticosteroids.

Discussion: The development of vaccines and immunization programs reduced the morbidity and mortality of several diseases. Other case reports suggested the possible association between myopathies and the administration of the hepatitis B vaccine and H1N1 plus the seasonal trivalent influenza and other vaccines. The exact mechanism is still unknown, but a presumable autoimmune phenomenon is incriminated.

Conclusion: The main purpose of this case report is to raise awareness about the possible link between the COVID-19 vaccination and polymyositis and the urge to take charge to avoid further complications.

Keywords: Vaccine, AZD1222, AstraZeneca, myositis, inflammatory myopathies, complication.

« Previous Next »
Graphical Abstract

[1]
Acute eosinophilic pneumonia associated with the anti-COVID-19 Vaccine AZD1222. Cureus 2021; 13(10): e18959.
[http://dx.doi.org/10.7759/cureus.18959]
[2]
Stübgen JP. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev 2014; 13(1): 31-9.
[http://dx.doi.org/10.1016/j.autrev.2013.08.005 ] [PMID: 24001753]
[3]
Ramírez-Rivera J, Vega-Cruz AM, Jaume-Anselmi F. Polymyositis: Rare complication of hepatitis B vaccination. An unusual cause of toxic shock syndrome. Bol Asoc Med P R 2003; 95(6): 13-6.
[PMID: 15449786]
[4]
Ferri C, Colaci M, Manzini CU, Sebastiani M, Giuggioli D, Brugioni L. Polymyositis following pandemic influenza A (H1N1) and 2009-10 seasonal trivalent vaccines. Case Rep Rheumatol 2012; 2012: 1-3.
[http://dx.doi.org/10.1155/2012/836930 ] [PMID: 22937458]
[5]
Shinjo SK, de Moraes JCB, Levy-Neto M, et al. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: Immunogenicity independent of therapy and no harmful effect in disease. Vaccine 2012; 31(1): 202-6.
[http://dx.doi.org/10.1016/j.vaccine.2012.10.063 ] [PMID: 23123020]
[6]
Orbach H, Tanay A. Vaccines as a trigger for myopathies. Lupus 2009; 18(13): 1213-6.
[http://dx.doi.org/10.1177/0961203309345734 ] [PMID: 19880571]

Rights & Permissions Print Cite
Article Metrics
25
2
© 2024 Bentham Science Publishers | Privacy Policy